Showing 1181-1190 of 1320 results for "".
- Immune Pharmaceuticals: FDA Accepts IND Application for Bertilimumab for Bullous Pemphigoidhttps://practicaldermatology.com/news/immune-pharmaceuticals-fda-accepts-ind-application-for-bertilimumab-for-bullous-pemphigoid/2458813/Immune Pharmaceuticals, Inc. has indicated that the FDA has accepted the Company's Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). This FDA acceptance enables the Company to expand recruitme
- Syneron Appoints Jeff Nardoci as President of North America Body Shaping Grouphttps://practicaldermatology.com/news/syneron-appoints-jeff-nardoci-as-president-of-north-america-body-shaping-group/2458820/Syneron Medical Ltd., a leading global aesthetic device company, appointed Jeff Nardoci as President of its North America Body Shaping Group. In this position, Mr. Nardoci will be responsible for the development and execution of the company's growth strategies for UltraShape and VelaShape. He
- LEO Pharma to Acquire Global Dermatology Portfolio from Astellashttps://practicaldermatology.com/news/leo-pharma-to-acquire-global-dermatology-portfolio-from-astellas/2458818/LEO Pharma A/S and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. Under the terms of the agreement, the assets and associated respon
- Lumenis UltraPulse Technology is Being Used to Treat Kim Phuc “The Girl in the Picture”https://practicaldermatology.com/news/lumenis-ultrapulse-technology-is-being-used-to-treat-kim-phuc-the-girl-in-the-picture/2458821/Lumenis Ltd.’s UltraPulse laser is being used by Jill Waibel, MD to treat scars on Kim Phuc, a survivor of a Vietnam War bombing in 1972. The UltraPulse was chosen for its effectiveness in laser scar revision therapy that is needed to penetrate deep into the thick scars. Kim Phuc, a
- New Tattoo Survey Shows Tattoo Acceptance Up; Tattoo Regret Still an Issuehttps://practicaldermatology.com/news/new-tattoo-survey-shows-tattoo-acceptance-up-tattoo-regret-still-an-issue/2458826/With nearly 40 percent of Americans ages 18-29 sporting ink, body art has not only become mainstream, but can actually up someone's stock. In a recent Syneron Candela survey, attitudes toward people with tattoos were overwhelmingly positive, being described as artistic and creative (50 percen
- Syneron Candela Announces New FDA Clearance for the CO2RE Systemhttps://practicaldermatology.com/news/syneron-candela-announces-new-fda-clearance-for-the-co2re-system/2458825/The FDA has granted numerous additional indications for use of Syneron Medical Ltd.’s CO2RE CO2 device. This clearance, including more than 90 specific indications in total, significantly expands the business opportunity for CO2RE users for high patient dema
- FDA Approves Yervoy for Adjuvant Treatment for Fully Resected Stage III Melanomahttps://practicaldermatology.com/news/fda-approves-yervoy-for-adjuvant-treatment-for-fully-resected-stage-iii-melanoma/2458829/The FDA approved Bristol-Myers Squibb Company’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1mm who have undergone complete resection including total lymphadenectomy. Th
- Phase 3 Data Show Promius Pharma's DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasishttps://practicaldermatology.com/news/phase-3-data-show-promius-pharmas-dfd-01-met-primary-endpoints-for-the-treatment-of-moderate-psoriasis/2458833/Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both stud
- Imlygic Approved for Melanoma; Available in a Weekhttps://practicaldermatology.com/news/imlygic-approved-for-melanoma-available-in-a-week/2458834/The FDA has approved the Biologics License Application for Amgen’s Imlygic™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after
- Now Available at Pharmacies: Bayer's Finacea® Foam 15%https://practicaldermatology.com/news/now-available-at-pharmacies-bayers-finacea-azelaic-acid-foam-15/2458835/Bayer HealthCare’s Finacea® (azelaic acid) Foam, 15% in now available at pharmacies nationwide. Finacea Foam was FDA approved in July 2015 for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval was based on results